Anti–VEGF antibody and NF-κB inhibitor Bay 11-7085 suppressed tumor growth and serum VEGF levels in K1 lymphoma–bearing BALB/c nu/nu mice. (A,C) K1 lymphoma subtransplants were generated by subcutaneously injecting tumor fragments (∼2 mm3) into BALB/c nu/nu mice from a primary lymphoma in a K1 transgenic mouse. To ascertain the effect of VEGF on tumor growth each tumor-bearing mouse (n = 6 per group) was given an anti–VEGF antibody (A, ▪) or normal rabbit IgG (15 μg/mouse each week; A, □) intraperitoneally. To ascertain the effect of NF-κB on tumor growth, tumor-bearing mice (n = 6 per group) were given Bay 11-7085 (100 μg/mouse; C, ▪) in 0.1 mL of DMSO, or DMSO alone (C, □), twice weekly intraperitoneally. The animals were killed after 3 weeks, and the tumors were recovered and weighed. (B,D) VEGF concentration in 50-μL aliquots of mouse sera was measured by ELISA. Statistically significant differences in tumor growth (A and C, bars 1 and 2) and serum VEGF levels (B and D) in tumor-bearing mice (bar 1) versus tumor-bearing mice treated with anti–VEGF antibody (B, bar 2) or Bay 11-7085 (C, bar 2), and nontumor-bearing mice (B, ▧) are shown with an asterisk (*).
